Article by Brem Devol
Immunotherapy Strengthens Fight Against Stage 4 Lung Cancer and Stage 4 Cancer
The field of cancer immunology is essentially more than 30 years in development and has experienced rapid advances, particularly over the last decade. Immunotherapy, the use of the stimulated immune system to rid disease, has branched into varied subsets including immune system growth factors, monoclonal antibodies, cellular therapies, and even combinations of two or more of these indicated strategies. Stellar progress in adoptive immunotherapy (focused on the expansion of specific disease-fighting white blood cells and their infusion into patients) have led to definitive discoveries that will prominently impact the treatment of and stage 4 cancers over the next decade.
15 percent of all cancer diagnoses is – making the disease easily the cause of death for men and women alike. The disease is also diagnosed in later stages than others as it takes longer to develop and usually appears in older individuals. There is no question that new treatment approaches are vital to getting control of this killer.
Current Stage 4 Treatment Issues and Outcomes – Immunotherapy a Great Option
Newly diagnosed patients are often faced with treatment options that commonly include surgery, radiation, chemotherapy, or some combination of all of them. Some patients are invited to participate in clinical trials when an investigational therapy is appropriate to one’s specific condition. However, let the patient beware. Anytime one sees a clinical trial option for , it may realistically viewed as a reliable indicator that the conventional therapies are not working well and patients have begun to seek other options.
Some light in the fog comes with the continued evolution of